STOK - Stoke Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
Total Revenue
0
0
0
Cost of Revenue
-
-
-
Gross Profit
-
-
-
Operating Expenses
Research Development
19,679
8,371
3,598
Selling General and Administrative
9,473
4,410
1,956
Total Operating Expenses
29,152
12,781
5,554
Operating Income or Loss
-29,152
-12,781
-5,554
Interest Expense
-
-
-
Total Other Income/Expenses Net
-
-10
-4
Income Before Tax
-26,447
-12,521
-5,558
Income Tax Expense
-
-
-
Income from Continuing Operations
-26,447
-12,521
-5,558
Net Income
-26,447
-12,521
-5,558
Net Income available to common shareholders
-26,447
-12,521
-5,558
Reported EPS
Basic
-
-0.98
-0.43
Diluted
-
-0.98
-0.43
Weighted average shares outstanding
Basic
-
12,785
12,785
Diluted
-
12,785
12,785
EBITDA
-
-12,567
-5,441